Ipamorelin vs Sermorelin: GHRP vs GHRH Comparison for Growth Hormone Research
Research comparison of Ipamorelin (GHRP/ghrelin mimetic) vs Sermorelin (GHRH analog) — complementary mechanisms, pulse characteristics, cortisol/prolactin differences, half-life comparison, and why combining both optimizes GH release research protocols.
TL;DR
- Sermorelin: GHRH analog — stimulates pituitary via GHRH receptor; ~12 minute half-life
- Ipamorelin: GHRP/ghrelin mimetic — stimulates via GHS-R1a receptor; ~2 hour half-life; NO cortisol/prolactin
- Combination is synergistic: GHRH + GHRP together produce much larger GH pulses than either alone
- Best practice: MOD GRF 1-29 (shorter-acting GHRH) + Ipamorelin for physiologically pulsatile GH release
Disclaimer: For educational and research purposes only — not medical advice.
Growth hormone secretagogue peptides divide into two mechanistic classes: GHRH analogs (stimulating pituitary GH release via GHRH receptors) and GHRPs (stimulating via ghrelin/GHS-R1a receptors). Sermorelin and Ipamorelin are the most widely used representatives of each class, and understanding their differences is essential for designing effective GH research protocols.
Sermorelin: GHRH Analog
Sermorelin is the biologically active first 29 amino acids (N-terminal) of native growth hormone-releasing hormone (GHRH 1-44). This fragment retains full GHRH biological activity — binding GHRH receptors on pituitary somatotrophs to stimulate GH synthesis and release.
Key characteristics:
- Half-life: ~10-12 minutes (very short — requires immediate pre-sleep or pre-workout timing)
- Mechanism: GHRH receptor agonist — amplifies the amplitude of physiological GH pulses
- Side effects: Generally minimal; rare: facial flushing, injection site reactions
- FDA status: Was approved as Geref for pediatric GH deficiency; discontinued commercially but available from compounding pharmacies
- Cortisol/Prolactin: No significant effect
The very short half-life of sermorelin is both a limitation (requires precise timing) and an advantage (rapid clearance with minimal receptor desensitization).
Ipamorelin: Selective GHRP
Ipamorelin is a pentapeptide GHRP discovered by Novo Nordisk in the 1990s, selected specifically for its high GH selectivity and minimal off-target effects. It mimics ghrelin's action at the GHS-R1a receptor on somatotrophs, stimulating GH release through a different intracellular signaling pathway than GHRH.
Key characteristics:
- Half-life: ~2 hours (much longer than other GHRPs; allows more flexibility in timing)
- Mechanism: GHS-R1a agonist — ghrelin receptor mimetic
- Cortisol/Prolactin: None — the critical differentiator from GHRP-2, GHRP-6, and Hexarelin
- Side effects: Mild hunger (especially at higher doses); water retention at high doses
- GH pulse amplitude: Moderate alone; dramatically amplified when combined with a GHRH
Side Effect Comparison
| Parameter | Sermorelin | Ipamorelin | GHRP-6 | GHRP-2 |
|---|---|---|---|---|
| GH Release | ++ | ++ | +++ | +++ |
| Cortisol | None | None | ++ (significant) | ++ (significant) |
| Prolactin | None | Minimal | ++ | + |
| Hunger | None | Mild | Significant | Mild |
| IGF-1 elevation | Moderate | Moderate | High | High |
| Half-life | ~12 min | ~2 hours | ~2 hours | ~2 hours |
Synergistic Combination Mechanism
GHRH and GHRPs act on different receptors but converge on cAMP/calcium-dependent pathways for GH secretion. When both are administered simultaneously:
- GHRH maximally stimulates GH synthesis and primes somatotrophs
- GHRP/ghrelin receptor activation amplifies the GH pulse through the calcium/PKC pathway
- The combined effect is multiplicative, not merely additive — producing GH pulses 3-10x larger than either compound alone
This is why the Ipamorelin + MOD GRF 1-29 combination is considered the most effective non-GH secretagogue stack for GH research.
Why MOD GRF 1-29 Instead of Sermorelin?
Modified GRF 1-29 (also called CJC-1295 without DAC) is sermorelin with 4 amino acid substitutions at positions susceptible to proteolytic degradation. These substitutions extend the half-life from ~12 minutes (sermorelin) to ~30 minutes, while maintaining full GHRH receptor activity.
For research practicality:
- Sermorelin: Must inject within 5 minutes of intended GH pulse timing; more sensitive to temperature
- MOD GRF 1-29: ~30 minute window; more robust
- Both are preferable to CJC-1295 with DAC for maintaining natural GH pulsatility
Research Dosing Protocol
Standard Ipamorelin + MOD GRF 1-29 stack:
- Dose: 100-300mcg of each, injected simultaneously in the same syringe
- Timing: Before sleep (capitalizes on sleep-dependent GH pulse) and/or post-exercise (20-30 min after)
- Frequency: 2x daily (pre-sleep + post-workout), or 1x daily pre-sleep for simpler protocols
- Reconstitute each in 2mL bacteriostatic water (2.5mg vial → 1.25mg/mL if using 5mg vials)
Frequently Asked Questions
Q: Can Sermorelin and Ipamorelin be combined in the same syringe? A: Yes — this is standard practice. Both are stable for short periods in the same syringe after reconstitution. Draw each compound into the same syringe and inject immediately.
Q: How long does it take to see effects from the Ipamorelin + GHRH combination? A: IGF-1 levels typically rise meaningfully within 4-6 weeks of twice-daily dosing, with subjective improvements in sleep quality often reported within 1-2 weeks. Body composition changes (lean mass, fat reduction) require 3-6 months of consistent use.
Use the Reconstitution Calculator → /calculators/reconstitution
For educational and research purposes only. Not medical advice.
Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.
Written by the Peptide Performance Calculator Research Team
Our team compiles research guides based on published literature for educational purposes. All content is for research use only — not medical advice. Read our disclaimer.
Frequently Asked Questions
What is the main mechanistic difference between Ipamorelin and Sermorelin?
Sermorelin is a GHRH analog (first 29 amino acids of growth hormone-releasing hormone) that stimulates somatotroph cells in the pituitary to release stored GH. Ipamorelin is a GHRP (growth hormone-releasing peptide) and ghrelin receptor mimetic that activates a different pathway — also stimulating GH release but through ghrelin receptors (GHS-R1a). When combined, they work synergistically through distinct mechanisms.
Does Ipamorelin cause cortisol or prolactin increases like other GHRPs?
This is Ipamorelin's most important distinguishing feature: it is highly selective for GH release with minimal or no effect on cortisol, prolactin, or ACTH at research doses. Other GHRPs — especially GHRP-6 and Hexarelin — significantly increase cortisol and prolactin, which can counteract anabolic effects. Ipamorelin's selectivity makes it the preferred GHRP for most research protocols.
Which works better for anti-aging GH optimization — Ipamorelin or Sermorelin?
Both are used in anti-aging/longevity protocols. Sermorelin better mimics the physiological GHRH signal; Ipamorelin provides the complementary ghrelin-mimetic GH pulse amplification. The combination of Ipamorelin + Modified GRF 1-29 (a shorter GHRH analog) is considered the gold standard for GH research protocols because it maximizes GH pulse amplitude while preserving pulsatility.
New compound guides and calculator updates — no spam, unsubscribe any time.
Free Peptide Calculators
7 free calculators covering reconstitution, dosage, syringe units, half-life, injection volume, stack planning, and cycle duration — no account needed.